<DOC>
	<DOCNO>NCT00070343</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dacarbazine , use different way stop tumor cell divide stop grow die . Oblimersen may help dacarbazine kill tumor cell make sensitive drug . PURPOSE : This clinical trial study well give oblimersen together dacarbazine work treat patient advanced malignant melanoma previously respond treatment oblimersen dacarbazine clinical trial GENTA-GM301 .</brief_summary>
	<brief_title>Oblimersen Dacarbazine Treating Patients With Advanced Malignant Melanoma That Has Responded Treatment Clinical Trial GENTA-GM301</brief_title>
	<detailed_description>OBJECTIVES : Primary - Provide continuation therapy oblimersen ( G3139 ) dacarbazine patient advance malignant melanoma obtain response stabilization disease prior treatment therapy GENTA-GM301 . Secondary - Determine serious adverse event patient treat regimen . OUTLINE : This nonrandomized , open-label , multicenter , continuation study . Patients receive oblimersen ( G3139 ) IV continuously day 1-5 dacarbazine IV 1 hour day 5 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients complete 8 course treatment may receive additional course discretion physician . Patients follow every 2 month 2 year initiation GENTA-GM301 protocol . PROJECTED ACCRUAL : A total 375 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignant melanoma Unresectable metastatic disease Previously enrol GENTAGM301 protocol Complete partial objective response stable disease completion 8 course oblimersen ( G3139 ) dacarbazine arm II GENTAGM301 Measurable evaluable disease No uncontrolled brain metastasis leptomeningeal disease PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3* Platelet count least 100,000/mm^3* Hemoglobin least 8 g/dL* NOTE : *Hematopoietic growth factor transfusion independent Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Albumin least 2.5 g/dL PTT great 1.5 time ULN PT great 1.5 time ULN OR INR great 1.3 No history chronic hepatitis cirrhosis Renal Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular No uncontrolled congestive heart failure No active symptom coronary artery disease , define uncontrolled arrhythmias recurrent chest pain despite prophylactic medication No New York Heart Association class III IV heart disease No cardiovascular sign symptom grade 2 great within past 4 week Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant medical disease No uncontrolled seizure disorder No active infection No uncontrolled diabetes mellitus No active autoimmune disease No known hypersensitivity phosphorothioatecontaining oligonucleotides dacarbazine No intolerance prior oblimersen dacarbazine , include discontinuation protocol therapy due 1 adverse event HIV negative Satisfactory venous access 5day continuous infusion Intellectually , emotionally , physically able maintain ambulatory infusion pump PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior biologic therapy , immunotherapy , cytokine therapy , vaccine therapy recover No concurrent anticancer biologic therapy Chemotherapy See Disease Characteristics No concurrent anticancer chemotherapy Endocrine therapy No concurrent chronic corticosteroid ( average dose least 20 mg/day prednisone equivalent ) Radiotherapy At least 4 week since prior radiotherapy recover No concurrent anticancer radiotherapy Surgery At least 4 week since prior major surgery recover Other At least 4 week since prior therapy recover More 3 week since prior experimental therapy ( except GENTAGM301 protocol ) No intervene systemic therapy melanoma since completion GENTAGM301 protocol therapy No concurrent anticancer therapy , include investigational therapy No concurrent immunosuppressive drug No concurrent anticoagulation therapy Concurrent warfarin ( 1 mg/day ) central line prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage III melanoma</keyword>
</DOC>